Published in J Clin Virol on April 23, 2007
Occult HBV infection. Semin Immunopathol (2012) 1.37
An overview of occult hepatitis B virus infection. World J Gastroenterol (2011) 1.32
Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev (2012) 1.30
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis (2008) 1.04
Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol (2009) 0.99
Occult hepatitis B virus infection. World J Hepatol (2014) 0.90
Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy. Biomed Res Int (2013) 0.84
Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol (2014) 0.84
Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy. Virol J (2010) 0.84
The clinical significance of occult HBV infection. Ann Gastroenterol (2014) 0.83
Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes. World J Gastroenterol (2011) 0.83
Prevalence of occult hepatitis B virus in plasma and peripheral blood mononuclear cell compartments of patients with chronic hepatitis C infection in tehran-iran. Hepat Mon (2013) 0.80
Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol (2008) 0.80
The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol (2015) 0.79
Diagnosis of hepatitis B. Ann Transl Med (2016) 0.77
Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient. Virol J (2011) 0.75
Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci (2008) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene (2003) 2.11
Neighborhood poverty and injection cessation in a sample of injection drug users. Am J Epidemiol (2010) 2.07
KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog (2006) 2.06
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLoS One (2012) 1.96
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS (2013) 1.92
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis (2005) 1.91
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis (2005) 1.89
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology (2007) 1.78
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology (2006) 1.59
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis (2003) 1.57
Tuberculosis-associated haemophagocytic syndrome. Lancet Infect Dis (2006) 1.55
Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. Hum Pathol (2013) 1.54
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
The Warburg effect: insights from the past decade. Pharmacol Ther (2012) 1.53
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52